ATM and P53 Regulate FOXM1 Expression via E2F in Breast Cancer Epirubicin Treatment and Resistance

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-11-0024
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2010English

Weekly Epirubicin in the Treatment of Gestational Breast Cancer (GBC)

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

DNA Damage Response-Related Proteins in Gastric Cancer: ATM, Chk2 and P53 Expression and Their Prognostic Value

Pathobiology
MedicineForensic MedicinePathologyCell BiologyMolecular Biology
2014English

Monitoring Treatment Efficacy and Resistance in Breast Cancer Patients via Circulating Tumor DNA Genomic Profiling

Molecular genetics & genomic medicine
GeneticsMolecular Biology
2019English

Aurora Kinase a Stabilizes FOXM1 to Enhance Paclitaxel Resistance in Triple‐negative Breast Cancer

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Epirubicin and Long-Term Heart Failure Risk in Breast Cancer Survivors

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2018English

P53 Expression and the Result of Adjuvant Therapy of Breast Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
1995English

P53 Expression as a Prognostic Marker in Inflammatory Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2004English

Novel Link Between E2F and P53: Proapoptotic Cofactors of P53 Are Transcriptionally Upregulated by E2F

Cell Death and Differentiation
Cell BiologyMolecular Biology
2005English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy